Table 2 Demographics and clinical characteristics 12 months prior to MITT initiation by MITT persistence.

From: Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain

 

MITT persistence (N = 754)

MITT step down (N = 361)

MITT discontinuation (N = 89)

Demographics

Female, n (%)

513 (68.0)

273 (75.6)

65 (73.0)

Age at asthma diagnosis, mean (SD)

45.13 (15.6)

45.4 (16.3)

45.37 (16.2)

Age at MITT initiation, mean (SD)

55.30 (13.2)

54.0 (14.5)

54.25 (15.2)

Years from diagnosis to MITT, mean (SD)

10.17 (9.2)

8.6 (8.2)

8.88 (8.5)

Urban location, n (%)

642 (85.1)

309 (85.6)

72 (80.9)

Smoking status, n (%)

Non-smoker

439 (58.2)

218 (60.4)

51 (57.3)

Smoker

134 (17.8)

52 (14.4)

22 (24.7)

Former smoker

153 (20.3)

79 (21.9)

15 (16.9)

Unknown

28 (3.7)

12 (3.3)

1 (1.1)

BMIa

n = 388

n = 213

n = 39

BMI, mean (SD) kg/m2

30.3 (6.1)

30.2 (6.3)

30.0 (6.4)

Spirometryb mean (SD)

n = 244

n = 124

n = 19

FEV1 % predicted value

69.4 (18.9)

72.9 (19.0)

74.2 (21.2)

FEV1/FVC ratio

69.1 (13.1)

71.5 (12.6)

74.5 (14.7)

Common comorbidities, n (%)

Anxiety/depression

281 (37.3)

150 (41.6)

28 (31.5)

Pneumonia

42 (5.6)

11 (3.0)

4 (4.5)

Other respiratory infections

225 (29.8)

118 (32.7)

30 (33.7)

Rhinitis

142 (18.8)

74 (20.5)

16 (18.0)

Hypertension

254 (33.7)

125 (34.6)

30 (33.7)

Diabetes mellitus

90 (11.9)

41 (11.4)

8 (9.0)

Gastroesophageal reflux

71 (9.4)

36 (10.0)

5 (5.6)

Conjunctivitis

67 (8.9)

44 (12.2)

10 (11.2)

Polyposis

53 (7.0)

21 (5.8)

2 (2.2)

Severe exacerbationsc, n (%)

421 (55.8)

199 (55.1)

47 (52.8)

Blood eosinophils (%), mean (SD)

n = 453

4.0 (3.5)

n = 232

4.4 (3.4)

n = 47 3.0

(1.9)

  1. BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, SD standard deviation, MITT multiple-inhaler triple therapy.
  2. aReported for patients with a BMI record in their medical history;
  3. breported for patients with spirometry measurements in their medical history;
  4. ca severe exacerbation was defined as the need for one hospitalization or emergency visit or the use of oral/systemic corticosteroids (or increase in the maintenance dose) for ≥3 days due to asthma.
Back to article page